Report of Foreign Issuer (6-k)
June 01 2020 - 8:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign
Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities
Exchange Act of 1934
June 2020
Commission file number:
001-36288
Akari Therapeutics,
Plc
(Translation of registrant's name into
English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive
offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
CONTENTS
On June 1, 2020, Akari Therapeutics,
Plc (the “Company”) announced that it will hold its Annual General Meeting of Shareholders on June 30, 2020. In connection
with the meeting, the Company furnished the following documents:
|
1.
|
Notice and Proxy Statement to Shareholders dated June 1, 2020
|
|
3.
|
Statutory Accounts for the year ended December 31, 2019
|
The information contained
in this report (including the exhibits hereto) is hereby incorporated by reference into all effective registration statements filed
by the Company under the Securities Act of 1933.
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Akari Therapeutics, Plc
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
Name:
|
Clive Richardson
|
|
|
Chief Executive Officer and Chief Operating Officer
|
Date: June 1, 2020
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024